This episode covers FDA clearances across imaging platforms in February twenty twenty-six, including RevealDx’s lung nodule characterization software with activated Medicare reimbursement, Nanox’s TAP2D enhancement for tomosynthesis systems, GE HealthCare’s Allia Moveo intervention imaging and MIM LesionID Pro for automated tumor burden analysis, and Aidoc’s comprehensive foundation model for multi-condition abdomen CT detection. The briefing concludes with an examination of Doctronic’s autonomous prescription renewal system in Utah, which operates without direct clinician input and claims exemption from FDA oversight under the practice of medicine doctrine, illustrating unresolved jurisdictional questions in AI-driven clinical decision-making.
